JNJ-10280205 and JNJ-10287069: Novel PDE5 inhibitors as clinical candidates for erectile dysfunction

International Journal of Impotence Research

Volumn 18, Issue 5, 2006, Pages 477-483

  Qiu, Y ^a   Bhattacharjee, S ^a   Kraft, P ^a   John, T Mathew ^a,b   Haynes Johnson, D ^a   Jiang, W ^a   Sui, Z ^a   Lundeen, S ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b ETHICON INC   (United States)

Author keywords

Erectile dysfunction; PDE5; PDE5 inhibitor

Indexed keywords

CYTOCHROME P450; JNJ 10280205; JNJ 10287069; PHOSPHODIESTERASE I; PHOSPHODIESTERASE III; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE V INHIBITOR; POTASSIUM CHANNEL HERG; SILDENAFIL; SPLEEN EXONUCLEASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR SYSTEM; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG INHIBITION; DRUG ISOLATION; DRUG METABOLISM; DRUG SELECTIVITY; ERECTILE DYSFUNCTION; IN VITRO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; 3',5'-CYCLIC-GMP PHOSPHODIESTERASES; ANIMALS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; CYTOCHROME P-450 ENZYME SYSTEM; DOGS; ENZYME INHIBITORS; ERECTILE DYSFUNCTION; ETHER-A-GO-GO POTASSIUM CHANNELS; HAPLORHINI; HUMANS; IMPOTENCE; MALE; QUINOLONES; RATS;

EID: 33748309156     PISSN: 09559930     EISSN: 14765489     Source Type: Journal    
DOI: 10.1038/sj.ijir.3901462     Document Type: Article

References (30)

1. Aboseif SR, Lue TF. Haemodynamics of penile erection. Urol Clin N Am 1988; 15: 1-7.
2. Ignarro LJ, Bush PA, Buga GM, Wood KS, Fukuto J, MRajfer J. Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res Comm 1990; 170: 843-850.
3. Kim N, Azadzoi KM, Goldstein I, Saenz de Tejada I. A nitric oxide-like factor mediates nonadrenergic-noncholinergic neurogenic relaxation of penile corpus cavernosum smooth muscle. J Clin Invest 1991; 88: 112-118.
4. Burnett AL, Lowenstein CJ, Bredt DS, Chang TS, Snyder SH. Nitric oxide: a physiologic mediator of penile erection. Science 1992; 257: 401-403.
5. Corbin JD, Francis SH. Cyclic GMP phosphodiesterase-5: target of sildenafil. J Biol Chem 1999; 274: 13729-13732.
6. Maggi M, Filippi S, Ledda F, Magini A, Forti G. Erectile dysfunction: from biochemical pharmacology to advances in medical therapy. Eur J Endocrinol 2000; 143: 143-154.
7. Francis SH, Turko IV, Corbin JD. Cyclic nucleotide phosphodiesterases: relating structure and function. Prog Nucleic Acid Res Mol Biol 2001; 65: 1-52.
8. O'Donnell JM. William Harvey Research Conference on PDE inhibitors: drugs with an expanding range of therapeutic uses. Exp Opin Invest Drugs 2000; 9: 621-625.
9. Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996; 8: 47-52.
10. Goldenberg MM. Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction. Clin Ther 1998; 20: 1033-1048.
11. Eardley I. New oral therapies for the treatment of erectile dysfunction. Br J Urol 1998; 81: 122-127.
12. Briganti A, Salonia A, Gallina A, Sacca A, Montorsi P, Rigatti P et al. Drug insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction. Nat Clin Pract Urol 2005; 2: 239-247.
13. Sui Z. Phosphodiesterase-5 inhibitors for male erectile dysfunction. Expert Opin Ther Patents 2003; 13: 1371-1388.
14. Jiang W, Guan J, Macielag M, Sui Z, Qiu Y, Kraft P et al. Pyrroloquinolone PDE5 inhibitors with improved pharmaceutical profiles for clinical studies on erectile dysfunction. J Med Chem 2005; 48: 2126-2133.
15. Qiu Y, Bahattacharjee S, Kraft P, John TM, Craig E, Haynes-Johnson D et al. Characterization of a novel phosphodiesterase type 5 inhibitor: JNJ-10258859. Eur J Pharm 2003; 472: 73-80.
16. D'Andrea MR, Qiu Y, Haynes-Johnson D, Bhattacharjee S, Kraft P, Lundeen S. Expression of PDE11A4 in normal and malignant human tissues. J Histochem Cytochem 2005; 53: 895-903.
17. Yan Z, Rafferty B, Caldwell GW, Masucci J. Rapidly distinguishing reversible and irreversible CYP450 inhibitors by using fluorometric kinetic analyses. Eur J Drug Metab Pharmacokinet 2002; 27: 281-287.
18. Hellstrom WJG, Overstreet JW, Yu A, Saikali K, Shen W, Beasley CMJ et al. Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones. J Urol 2003; 170: 887-891.
19. Saenz de Tejada I, Angulo J, Cuevas P, Fernandez A, Moncada I, Allona A et al. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impotence Res 2001; 13: 282-290.
20. Daugan A, Grondin P, Ruault C, Le Monnier de Gouville AC, Coste H et al. The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[ 1′,2′:1,6]pyrido[3,4-b]indole-1,4- dione analogue. J Med Chem 2003; 46: 4533-4542.
21. Montorsi F, Salonia A, Briganti A, Barbieri L, Zanni G, Suardi N et al. Vardenafil for the treatment of erectile dysfunction: a critical review of the literature based on personal clinical experience. Eur Urol 2005; 47: 612-621.
22. Ormrod D, Easthope SE, Figgitt DP. Vardenafil. Drugs Aging 2002; 19: 217-227.
23. Fawcett L, Baxendale R, Stacey P, McGrouther C, Harrow I, Soderling S et al. Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. Proc Natl Acad Sci USA 2000; 97: 3702-3707.
24. Hetman JM, Robas N, Baxendale R, Fidock M, Phillips SC, Soderling SH et al. Cloning and characterization of two splice variants of human phosphodiesterase 11A. Proc Natl Acad Sci USA 2000; 97: 12891-12895.
25. Yuasa K, Kotera J, Fujishige K, Michibata H, Sasaki T, Omori K. Isolation and characterization of two novel phosphodiesterase PDE11A variants showing unique structure and tissue-specific expression. J Biol Chem 2000; 275: 31469-31479.
26. Maw GN, Allerton CMN, Gbekor E, Million WA. Design, synthesis and biological activity of [beta]-carboline-based type-5 phosphodiesterase inhibitors. Bioorg Med Chem Lett 2003; 13: 1425-1428.
27. Weeks JL, Zoraghi R, Beasley A, Sekhar KR, Francis SH, Corbin JD. High biochemical selectivity of tadalafil, sildenafil and vardenafil for human phosphodiesterase 5A1 (PDE5) over PDE11A4 suggests the absence of PDE11A4 cross-reaction in patients. Int J Impot Res 2005; 17: 5-9.
28. Walker DK, Ackland MJ, James GC, Muirhead GJ, Rance DJ, Wastall P et al. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica 1999; 29: 297-310.
29. Pryor J. Vardenafil: update on clinical experience. Int J Impot Res 2002; 14(Suppl 1): S65-S69.
30. Padma-Nathan H. Efficacy and tolerability of tadalafil, a novel phosphodiesterase 5 inhibitor, in treatment of erectile dysfunction. Am J Cardiol 2003; 92: 19-25.